ANRS Maladies Infectieuses Emergentes

6 trials 3 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

5 Countries active

10 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 1 Phase II: 2 Phase I: 2 Phase I (Other): 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

COVID-19 prophylaxis 1 Hepatitis B e antigen negative 1

Top IMPs

10-1074-LS 1 ENTECAVIR 1 SELGANTOLIMOD 1 TENOFOVIR ALAFENAMIDE 1 TENOFOVIR DISOPROXIL 1 TEROPAVIMAB 1

All trials

6 total

An Experimental Medicine multicenter Trial to evaluate the safety and immunogenicity of experimental versus authorized SARS-CoV-2 vaccine ca… Recruiting

2025-520652-28-00 Phase I 1 country
MODULO Recruiting

2024-515793-27-01 Phase III 1 country
A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus… Recruiting

2024-516150-22-00 Phase II 1 country 10-1074-LS; TEROPAVIMAB
A phase 1/2a multicenter trial to evaluate the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster in adu… Ended

2024-516767-92-01 Phase I 1 country
A pilot open label phase I trial to evaluate the safety and the tolerability of a combination of two HIV-1 inducers in HIV+ sub-type B patie… Ended

2024-518141-13-00 Phase I (Other) 1 country
ANRS HB07 IP-Cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC d… Ended

2024-515739-32-00 Phase II 4 countries ENTECAVIR; SELGANTOLIMOD; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL

Showing 1–6 of 6 trials

← All sponsors A–Z